BR112017010101A2 - uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central - Google Patents

uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central

Info

Publication number
BR112017010101A2
BR112017010101A2 BR112017010101A BR112017010101A BR112017010101A2 BR 112017010101 A2 BR112017010101 A2 BR 112017010101A2 BR 112017010101 A BR112017010101 A BR 112017010101A BR 112017010101 A BR112017010101 A BR 112017010101A BR 112017010101 A2 BR112017010101 A2 BR 112017010101A2
Authority
BR
Brazil
Prior art keywords
central nervous
checkpoint inhibitors
neoplasms
nervous system
immune system
Prior art date
Application number
BR112017010101A
Other languages
English (en)
Portuguese (pt)
Inventor
CHENG Shinta
Coric Vladimir
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112017010101A2 publication Critical patent/BR112017010101A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112017010101A 2014-12-16 2015-12-16 uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central BR112017010101A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092783P 2014-12-16 2014-12-16
US201562261130P 2015-11-30 2015-11-30
PCT/US2015/066177 WO2016100561A2 (en) 2014-12-16 2015-12-16 Use of immune checkpoint inhibitors in central nervous systems neoplasms

Publications (1)

Publication Number Publication Date
BR112017010101A2 true BR112017010101A2 (pt) 2018-01-02

Family

ID=56127849

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017010101A BR112017010101A2 (pt) 2014-12-16 2015-12-16 uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central

Country Status (9)

Country Link
US (3) US20180133313A1 (cg-RX-API-DMAC7.html)
EP (1) EP3233123A4 (cg-RX-API-DMAC7.html)
JP (2) JP2018500332A (cg-RX-API-DMAC7.html)
CN (1) CN106999590A (cg-RX-API-DMAC7.html)
BR (1) BR112017010101A2 (cg-RX-API-DMAC7.html)
CA (1) CA2969338A1 (cg-RX-API-DMAC7.html)
MX (1) MX2017007390A (cg-RX-API-DMAC7.html)
RU (1) RU2726996C1 (cg-RX-API-DMAC7.html)
WO (1) WO2016100561A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014361473B2 (en) 2013-12-12 2019-09-26 Jiangsu Hengrui Medicine Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
EP3288980B1 (en) * 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
RS60792B1 (sr) 2015-05-29 2020-10-30 Agenus Inc Anti-ctla-4 antitela i postupci za njihovu primenu
UA124379C2 (uk) 2015-08-11 2021-09-08 Усі Байолоджікс Айрленд Лімітед Нові антитіла проти білка pd-1
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
US11209441B2 (en) 2016-04-05 2021-12-28 Bristol-Myers Squibb Company Cytokine profiling analysis
WO2018029124A1 (en) * 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
GB201618291D0 (en) * 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
EP3548030A4 (en) * 2016-12-05 2020-08-12 G1 Therapeutics, Inc. PRESERVATION OF THE IMMUNE RESPONSE DURING CHEMOTHERAPEUTIC DIETS
EP3551225A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Antibodies and methods of use thereof
MD3551660T2 (ro) 2016-12-07 2024-03-31 Agenus Inc Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
DE102017119868B4 (de) * 2017-07-12 2021-05-27 Bruker Daltonik Gmbh Feuchtestabilisierung bei der Präparation von Proben für die Spektrometrie
JP7159007B2 (ja) * 2017-11-01 2022-10-24 小野薬品工業株式会社 脳腫瘍の治療のための医薬
EP3774911A1 (en) * 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
WO2019230919A1 (ja) * 2018-05-31 2019-12-05 小野薬品工業株式会社 免疫チェックポイント阻害薬の有効性判定バイオマーカー
WO2020191240A1 (en) * 2019-03-19 2020-09-24 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
CA3152250A1 (en) * 2019-09-10 2021-03-18 Novocure Gmbh A method of reducing viability of cancer cells by applying alternating electric fields and administering checkpoint inhibitors to the cancer cells
US20230348599A1 (en) * 2019-12-19 2023-11-02 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
US20230045616A1 (en) * 2019-12-27 2023-02-09 Nonprofit Organization North East Japan Study Group Cancer treatment method and medicine
CN115697374A (zh) * 2020-05-12 2023-02-03 得克萨斯州大学系统董事会 用于治疗胶质母细胞瘤的方法
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022032312A1 (en) * 2020-08-07 2022-02-10 Northwestern University Methods of treating malignant glioblastoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010027423A2 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
HUE030807T2 (en) * 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
RU2402360C1 (ru) * 2009-07-08 2010-10-27 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ лечения злокачественной глиомы головного мозга
CN102178676B (zh) * 2011-04-29 2012-07-25 山东大学 一种治疗脑胶质瘤的药物组合物
WO2012177624A2 (en) * 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US10392442B2 (en) * 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

Also Published As

Publication number Publication date
CN106999590A (zh) 2017-08-01
US20240238416A1 (en) 2024-07-18
JP2021181482A (ja) 2021-11-25
MX2017007390A (es) 2017-11-06
EP3233123A4 (en) 2018-05-09
JP2018500332A (ja) 2018-01-11
EP3233123A2 (en) 2017-10-25
WO2016100561A2 (en) 2016-06-23
US20180133313A1 (en) 2018-05-17
US20210000953A1 (en) 2021-01-07
WO2016100561A3 (en) 2016-08-18
CA2969338A1 (en) 2016-06-23
RU2726996C1 (ru) 2020-07-17

Similar Documents

Publication Publication Date Title
BR112017010101A2 (pt) uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
MX2017005553A (es) Terapia de combinacion para cancer.
MX2016010080A (es) Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer.
BR112017017927A2 (pt) receptores quiméricos de antígenos anti-dll3 e métodos de uso
DOP2019000165A (es) Anticuerpos anti-ox40 y sus usos
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
CO2018000244A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
CO2017010618A2 (es) Anticuerpos contra icos
BR112017011932A8 (pt) Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
MX2024006565A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
BR112019008494A2 (pt) anticorpos para pd-1 e usos dos mesmos
BR112016014952A2 (pt) Inibição direcionada de tgfbeta
CO2018012699A2 (es) Anticuerpos anti-cd40 y sus usos
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
MX376078B (es) Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer.
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
BR112017009517A2 (pt) receptores de antígeno quimérico anti-cldn e métodos de uso
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements